Search

Home > GRACEcast Lung Cancer Video > Can we target KRAS effectively in advanced NSCLC?
Podcast: GRACEcast Lung Cancer Video
Episode:

Can we target KRAS effectively in advanced NSCLC?
Category: Science & Medicine
Duration: 00:04:04
Publish Date: 2013-07-02 06:43:49
Description:

Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.
Total Play: 0